Novacyt - NCYT Share Forecast, Price & News

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

Novacyt Stock Performance

NCYT traded down GBX 0.33 ($0.00) during trading on Thursday, hitting GBX 116.72 ($1.41). The stock had a trading volume of 58,242 shares, compared to its average volume of 355,862. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.74 and a current ratio of 4.08. The firm has a market capitalization of £82.43 million and a P/E ratio of -8.30. The company's 50-day moving average price is GBX 132.49 and its 200 day moving average price is GBX 166.27. Novacyt has a twelve month low of GBX 104.73 ($1.27) and a twelve month high of GBX 497.30 ($6.01).

Insider Buying and Selling

In related news, insider James Wakefield bought 7,000 shares of the firm's stock in a transaction that occurred on Thursday, July 7th. The shares were acquired at an average cost of GBX 117 ($1.41) per share, with a total value of £8,190 ($9,896.09).